Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2

Status

Terminated 10Recruiting 6Completed 6Withdrawn 4No longer available 2Approved for marketing 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Gynecologic 1Endocrine 1Breast 1

Conditions

Unspecified Adult Solid Tumor 1Triple Negative Breast Neoplasms 1Solid Tumors 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Endometrial Neoplasms 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × TIC10 compound × Clear all
NCT03932643 2026-01-20

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

University of Nebraska

Phase 1 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03034200 2024-11-26

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Case Comprehensive Cancer Center

Phase 2 Completed
30 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 15 charts
BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02609230 2021-06-04

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Fox Chase Cancer Center

Phase 1 Completed
33 enrolled
Plasma cell

Multiple Myeloma

NCT02250781 2019-05-22

Oral ONC201 in Treating Patients With Advanced Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
58 enrolled
Other solid neoplasm

Solid Tumors

NCT02324621 2019-05-22

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
26 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡